Ashkan Shoamanesh, MD

Associate professor of neurology at McMaster University.

Articles by Ashkan Shoamanesh, MD

What Asundexian’s Approval Means for Secondary Stroke Prevention at the Bedside: Ashkan Shoamanesh, MD

ByAshkan Shoamanesh, MD,Isabella Ciccone, MPH

November 11th 2026

The professor of medicine at McMaster University discussed the significance of asundexian’s approval, how a stroke-specific dose-finding approach shaped its development, and what OCEANIC-STROKE showed. [WATCH TIME: 6 minutes]

Secondary Analyses of ANNEXA-I Trial Assessing Andexanet Alfa in Intracranial Hemorrhage: Ashkan Shoamanesh, MD

ByAshkan Shoamanesh, MD

February 28th 2024

The associate professor of neurology at McMaster University talked about findings from secondary analyses on the phase 4 ANNEXA-I trial assessing andexanet alfa in patients with acute intracerebral hemorrhage. [WATCH TIME: 10 minutes]

Ashkan Shoamanesh, MD

Articles by Ashkan Shoamanesh, MD

What Asundexian’s Approval Means for Secondary Stroke Prevention at the Bedside: Ashkan Shoamanesh, MD

Secondary Analyses of ANNEXA-I Trial Assessing Andexanet Alfa in Intracranial Hemorrhage: Ashkan Shoamanesh, MD

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention

FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy

New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients

New York Forum Tackles Unmet Needs in Multiple Sclerosis Care

Examining High-Dose Influenza Vaccination and Alzheimer Disease Risk